Skip to main content
Addgene
Open Menu

pT3-EF1a-MYC-IRES-CRE
(Plasmid #252085)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 252085 Standard format: Plasmid sent in bacteria as agar stab 1 $94
Add to Cart

Backbone

  • Vector backbone
    pT3-EF1a
  • Backbone size w/o insert (bp) 3107
  • Total vector size (bp) 8495
  • Vector type
    Mammalian Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Low Copy

Gene/Insert

  • Gene/Insert name
    MYC
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    3700
  • Entrez Gene
    MYC (a.k.a. MRTL, MYCC, bHLHe39, c-Myc)
  • Promoter Ef1a

Cloning Information

Resource Information

  • A portion of this plasmid was derived from a plasmid made by
    This plasmid was synthesized by Synthego.

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry

Trademarks:

  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Please visit https://https://doi.org/10.1101/2025.07.29.667471 for bioRxiv preprint.

The Addgene sequence result contains f1 ori, while the depositor provided reference does not. Additionally, the region with AmpR and ori is inverted in the Addgene sequence result when compared to depositor-provided reference sequence.The depositor confirms these discrepancies do not affect plasmid function.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pT3-EF1a-MYC-IRES-CRE was a gift from Andrei Goga (Addgene plasmid # 252085 ; http://n2t.net/addgene:252085 ; RRID:Addgene_252085)

  • For your References section:

    Alanine catabolism as a targetable vulnerability for MYC-driven liver cancer. Montoya T, Lee JV, Qiu L, Krall A, Matulionis N, Seo Y, Finck BN, Kelley RK, Christofk H, Goga A. bioRxiv [Preprint]. 2025 Aug 12:2025.07.29.667471. doi: 10.1101/2025.07.29.667471. 10.1101/2025.07.29.667471 PubMed 40766546
Related items: